US92337F1075
© BusinessWire
11.01.2026
VCYT
LISTED
NASDAQ
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.
Preliminary Unaudited Financial Results
For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report:...
Themefolio
Profiler
Peergroup
© BusinessWire
29.12.2025
VCYT
LISTED
NASDAQ
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time.
Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.ver...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
VCYT
LISTED
NASDAQ
Veracyte to Participate in Upcoming Investor Conferences
News Preview
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
Wolfe Research Healthcare Conference – New York, NY
Fireside Chat on November 17th at 10:00 a.m. Eastern Time
Jefferies Global Healthcare Conference – London, UK
Fireside Chat on November 20th at 11:30...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
04.11.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Third Quarter 2025 Financial Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.
“We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Verac...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
03.11.2025
VCYT
LISTED
NASDAQ
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool’s ability to help define the future of thyroid nodule evaluation. Using the company’s innovative whole-transcriptome-derived research-use-only...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
VCYT
LISTED
NASDAQ
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m....
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
VCYT
LISTED
NASDAQ
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a molecular signature to predict hormone therapy benefit in men with recurrent prostate cancer will be presented at ASTRO 2025, the annual meeting of the American Society for Radiation Oncology. The findings were der...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2025
VCYT
LISTED
NASDAQ
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 12 Afirma-related abstracts will be presented at the 2025 American Thyroid Association Annual Meeting, taking place September 10-14 at the Westin Kierland in Scottsdale, Ariz. The large number of abstracts stems from Veracyte’s extensive database of thyroid-n...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
VCYT
LISTED
NASDAQ
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time.
A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte....
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
VCYT
LISTED
NASDAQ
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in Cell show that the Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2025
VCYT
LISTED
NASDAQ
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test. The milestone marks an important step in Veracyte’s goal of making the novel molecular test widely available and helping clin...
Themefolio
Profiler
Peergroup
© BusinessWire
17.07.2025
VCYT
LISTED
NASDAQ
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025 after the close of market on Wednesday, August 6, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
08.07.2025
VCYT
LISTED
NASDAQ
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that three Afirma-related abstracts will be presented at ENDO 2025, the annual meeting of the Endocrine Society, taking place July 12-15 in San Francisco. The findings are derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) database an...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findin...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
VCYT
LISTED
NASDAQ
Veracyte to Participate in Upcoming Investor Conferences
News Preview
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
William Blair 45th Annual Growth Stock Conference – Chicago, IL
Presentation on June 3rd at 5:40 p.m. Eastern Time
Jefferies Global Healthcare Conference – New York, NY
Presentation on June 4th at 2:00...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
VCYT
LISTED
NASDAQ
Veracyte Announces First Quarter 2025 Financial Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025.
"We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte’s chief executive officer. “With s...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression t...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2025, the annual meeting of the American Urological Association, taking place April 26-29 in Las Vegas. Study findings to be presented inc...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from its market-leading Decipher Prostate Genomic Classifier are available in a new specialized database that the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) Program just released. This database will enable elig...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
VCYT
LISTED
NASDAQ
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eas...
Themefolio
Profiler
Peergroup
© BusinessWire
25.03.2025
VCYT
LISTED
NASDAQ
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer in patients treated for muscle-invasive bladder cancer (MIBC) with more accuracy than ddPCR-based blood testing and earlier compared t...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that multiple abstracts will be presented at the 40th Annual European Association of Urology Congress (EAU25) demonstrating the clinical performance and utility of its Decipher tests in prostate and bladder cancer. Additionally, independent performance data suppor...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
VCYT
LISTED
NASDAQ
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024.
“I’m incredibly proud of what our team accomplished in 2024,” said Marc Stapley, Veracyte’s chief executive officer. “We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
VCYT
LISTED
NASDAQ
Veracyte to Participate in Upcoming Investor Conferences
News Preview
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
Raymond James 46th Annual Institutional Investors Conference – Orlando, FL
Presentation on March 5th at 9:50 a.m. Eastern Time
Leerink Partners Global Healthcare Conference – Miami, FL
Fireside Chat on...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
VCYT
LISTED
NASDAQ
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer. Presented...
Themefolio
Profiler
Peergroup
© BusinessWire
11.02.2025
VCYT
LISTED
NASDAQ
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU). The findings demonstrate the market leadership of its Decipher tests in better informing treatment decisions for patients with prostate and bladder can...
Themefolio
Profiler
Peergroup
© BusinessWire
05.02.2025
VCYT
LISTED
NASDAQ
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype. The findings, published in European Urology Open Science, show that the tes...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
VCYT
LISTED
NASDAQ
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update a...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
VCYT
LISTED
NASDAQ
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as part of the updated “Advanced Tools” table located in the Pri...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
VCYT
LISTED
NASDAQ
Veracyte Announces Third Quarter 2024 Financial Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2024.
"The strong momentum across our testing business continued during the third quarter as we delivered record revenue along with profitability and cash generation,” said Marc Stapley, Veracyte’s chief executive officer. “Looking ahead, we...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
VCYT
LISTED
NASDAQ
Veracyte to Participate in Upcoming Investor Conferences
News Preview
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.
UBS Healthcare Conference – Rancho Palos Verdes, CA
Fireside Chat on November 12th at 2:45 p.m. Eastern Time
Guggenheim Inaugural Healthcare Innovation Conference – Boston, MA
Fireside Chat on Novembe...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2024
VCYT
LISTED
NASDAQ
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m...
Themefolio
Profiler
Peergroup
© BusinessWire
02.10.2024
VCYT
LISTED
NASDAQ
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
VCYT
LISTED
NASDAQ
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial show that its Decipher Prostate Genomic Classifier is prognostic for clinical outcomes and predicts benefit from docetaxel in patients with metastatic prostate cancer. The f...
Themefolio
Profiler
Peergroup
© BusinessWire
04.09.2024
VCYT
LISTED
NASDAQ
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent S...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
VCYT
LISTED
NASDAQ
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time.
A live audio webcast of the company’s presentation will be...
Themefolio
Profiler
Peergroup
© BusinessWire
26.08.2024
VCYT
LISTED
NASDAQ
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle. The award marks the 11th consecutive year that Veracyte has received this honor.
The Bay Area Top Workplace award winners are determined based solely on employee feedback gathered by...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
